Metastatic Cancer Research
NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapiesPosted: June 4, 2018
The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.
Experimental Cancer Drug Metarrestin Targets Metastatic TumorsPosted: May 29, 2018
Researchers have struggled to develop therapies to treat tumors that have spread to other parts of the body. In a new study, researchers tested whether the experimental drug metarrestin can selectively shrink metastases in mouse models of aggressive pancreatic cancer.
Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory CancerUpdated: December 13, 2017
In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.
Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra KaplanPosted: September 20, 2017
NCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.
Modified Stem Cells Deliver Chemotherapy to Metastatic TumorsPosted: August 30, 2017
Researchers have used modified stem cells to deliver a cancer drug selectively to metastatic breast cancer tumors in mice. The stem cells target metastatic tumors by homing in on the stiff environment that typically surrounds them.
Study Identifies Genetic Mutations in Tumors From 10,000 Patients with Metastatic CancerPosted: May 31, 2017
Researchers at Memorial Sloan Kettering Cancer Center have reported the results of an initiative to characterize the genetic mutations in tumors from more than 10,000 patients with advanced cancer treated at the center.
Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis ComplicationsPosted: January 30, 2017
In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
Immune-Cell Traps May Aid Cancer MetastasisPosted: December 6, 2016
Cancer cells may exploit a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors, a new study suggests.
Whole Brain Radiation for Some Patients with Brain Metastases Worsens Cognitive DeclinePosted: June 2, 2015
In some patients with cancer that has spread to the brain, whole brain radiation following radiosurgery causes more severe cognitive decline and does not improve survival compared with radiosurgery alone, a new study has found.
Genetically Engineered Immunotherapy for Advanced CancerPosted: August 7, 2012
In this trial, doctors will collect T lymphocytes from the blood of patients with advanced mesothelin-expressing cancer and genetically engineer these cells to recognize mesothelin. The gene-engineered cells will then be multiplied and infused into the patients to fight their cancer.
Matters of the Heart: Why Are Cardiac Tumors So Rare?Posted: February 10, 2009
Cardiac tumors that originate in the heart itself are extremely rare. The highly specialized and most abundant cell in the heart may explain why the organ is such an inhospitable host to cancer.